程序始于杰富瑞估值持有

2024-11-15 02:35

Shares of PROCEPT BioRobotics (NASDAQ:PRCT) fell ~4% on Thursday after Jefferies launched the surgical robotics company with a Hold recommendation and $95 per share target, citing concerns over its valuation,
Jefferies analyst Michael Sarcone wrote that PROCEPT, which markets the HYDROS Robotic System to treat enlarged prostates, has risen more than 120% this year and over 42% since mid-August when the FDA cleared its next-gen Hydros system.
The company currently trades 15x 2025 sales, compared to the high-growth peer group's average of 11x. This implies a ~30% premium attributed to the company's peer-beating three-year CAGR, which stands ~31% above the group.
Citing channel checks, the firm suggests that the new Hyros product cycle could generate adoption among surgeons and lead to a replacement cycle among those using the older systems. However, "PRCT's current valuation levels could limit share (price) upside," Sarcone added.

More on Procept